Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Atriance Nelarabine Cancelled
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Xolair Omalizumab Asthma, severe persistent Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Xeljanz tofacitinib Cancelled
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
Cyramza Ramucirumab Cancelled
Onivyde Nanoliposomal Irinotecan Cancelled
Duobrii Halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Zejula Niraparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete